Funding for this research was provided by:
Austrian Science Fund (KLI 710, KLI 764)
Received: 8 May 2020
Accepted: 21 October 2020
First Online: 13 November 2020
: The authors declare the following competing financial interests: E.H. and M.R.S. have an unrelated sponsored research agreement with Servier within CANCER-ID, a project funded by the Innovative Medicines Joint Undertaking (IMI JU). E.H. receives funding from Freenome, South San Francisco, CA and PreAnalytiX, Hombrechtikon, Switzerland. The other authors have no competing interests to declare.